Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2020

01-07-2020 | Warfarin

Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol

Authors: L. Fuh, J. N. Goldstein, B. D. Hayes

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2020

Login to get access

Abstract

Patients who require urgent warfarin reversal often receive four-factor prothrombin complex concentrate (4F-PCC), which is traditionally dosed according to weight and initial INR. Our institution implemented a fixed-dose 4F-PCC strategy, using an initial dose of 1500 units. We evaluated the frequency with which the initial fixed dose 4F-PCC was inadequate, as defined by need for supplemental dosing. As part of the protocol, if the initial fixed-dose 4F-PCC is administered and does not achieve INR goal, then the remainder of the standard weight- and INR-based dosing can be given. During the study period, 63 patients on warfarin received 4F-PCC using the fixed-dose protocol. Based on the INR following 4F-PCC administration, 11 patients (17%) were eligible to receive a supplemental dose based on failure to achieve their specified INR goal. Two of the 11 patients eligible for supplemental 4F-PCC dosing received the second dose, both with initial supratherapeutic INRs > 3.5. We found that most patients given an initial fixed-dose 4F-PCC achieved their INR goals, and of those who did not, most did not receive supplemental dosing, suggesting that clinical providers felt that adequate hemostasis had been achieved. In addition, fixed-dose 4F-PCC was able to be given rapidly, with few dosing errors, suggesting that this is a reasonable option for 4F-PCC delivery.
Literature
1.
go back to reference Corio JL, Sin JH, Hayes BD, Goldstein JN, Fuh L (2018) Impact of a pharmacist-driven prothrombin complex concentrate protocol on time to administration in patients with warfarin-associated intracranial hemorrhage. West J Emerg Med. 19(5):849–854CrossRef Corio JL, Sin JH, Hayes BD, Goldstein JN, Fuh L (2018) Impact of a pharmacist-driven prothrombin complex concentrate protocol on time to administration in patients with warfarin-associated intracranial hemorrhage. West J Emerg Med. 19(5):849–854CrossRef
2.
go back to reference Tomaselli GF, Mahaffey KW, Cuker A et al (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70(24):3042–3067CrossRef Tomaselli GF, Mahaffey KW, Cuker A et al (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70(24):3042–3067CrossRef
3.
go back to reference Klein L, Peters J, Miner J, Gorlin J (2015) Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med 33(9):1213–1218CrossRef Klein L, Peters J, Miner J, Gorlin J (2015) Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med 33(9):1213–1218CrossRef
4.
go back to reference Varga C, Al-Touri S, Papadoukakis S, Caplan S, Kahn S, Blostein M (2013) The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. Transfusion. 53(7):1451–1458CrossRef Varga C, Al-Touri S, Papadoukakis S, Caplan S, Kahn S, Blostein M (2013) The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. Transfusion. 53(7):1451–1458CrossRef
5.
go back to reference Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K (2017) Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis. Neurocrit Care 26(1):64–69CrossRef Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K (2017) Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis. Neurocrit Care 26(1):64–69CrossRef
6.
go back to reference Wozniak M, Kruit A, Padmore R, Giulivi A, Bormanis J (2012) Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol. Transfus Apher Sci. 46:309–314CrossRef Wozniak M, Kruit A, Padmore R, Giulivi A, Bormanis J (2012) Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol. Transfus Apher Sci. 46:309–314CrossRef
7.
go back to reference Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K (2012) An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 97(10):1501–1506CrossRef Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K (2012) An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 97(10):1501–1506CrossRef
8.
go back to reference Frontera JA, Lewin JJ III, Rabinstein AA et al (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24:6–46CrossRef Frontera JA, Lewin JJ III, Rabinstein AA et al (2016) Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24:6–46CrossRef
9.
go back to reference Kcentra® [package insert]. Kankakee, IL: CSL Behring LLC; 2018 Kcentra® [package insert]. Kankakee, IL: CSL Behring LLC; 2018
10.
go back to reference Hirri HM, Green PJ (2014) Audit of warfarin reversal using a new Octaplex reduced dose protocol. Transfus Apher Sci. 51(2):141–145CrossRef Hirri HM, Green PJ (2014) Audit of warfarin reversal using a new Octaplex reduced dose protocol. Transfus Apher Sci. 51(2):141–145CrossRef
11.
go back to reference Astrup G, Sarangarm P, Burnett A (2018) Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis. J Thromb Thrombolysis 45:300–305CrossRef Astrup G, Sarangarm P, Burnett A (2018) Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis. J Thromb Thrombolysis 45:300–305CrossRef
Metadata
Title
Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol
Authors
L. Fuh
J. N. Goldstein
B. D. Hayes
Publication date
01-07-2020
Publisher
Springer US
Keyword
Warfarin
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2020
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01984-w

Other articles of this Issue 1/2020

Journal of Thrombosis and Thrombolysis 1/2020 Go to the issue